Obermatt
See Similar Stocks →

Flags

Earnings warning

HUTCHMED (China)

HKG:13 · KYG4672N1198
PharmaceuticalsMedium

360

27
Profit price62
Owner Earnings Yield100
Dividend Yield1
Price/Sales23
EV / Gross Profit22
Price/Book37
Return on Capital29
Cash Return on Capital96
Return on Equity96
EBIT Margin9
Gross Profitability11
Cash Conversion1
Accruals10
Owner Earnings Margin98
Sales growth76
Profit Growth44
Owner Earnings Growth59
Reinvestment56
Price momentum18
Debt load79
Refinancing1
Debt Payback100
Liquidity10
Analyst ratings55
Opinion Changes50
Price Target Upside94
Market mood53
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

HUTCHMED (China) doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryHong Kong SAR China
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeAIM
Founded2000
Employees288
Websitehutch-med.com
ISINKYG4672N1198
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
HematologyImmunologyRheumatologyInflammationGeneticsNutraceuticalOncologyBiopharmaBiotechnologyHealth CareMedicalPharmaceutical

Description

HUTCHMED (China) Limited (HUTCHMED), a global commercial-stage biopharmaceutical company, focuses on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of patients with cancer and immunologica…

Analysis

Middle-of-the-road

HUTCHMED (China) Limited sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is attractive. The owner-earnings multiple stands at 4.1×; owner earnings: the cash an owner could take out each year.

Growth is tepid; the safety picture is adequate. The company scores 4/20 on our value-creation score: not creating value.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
6
2026

All-time high

13

Mar 2026

All-time low

6

Jun 2026

Average rank

10

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
23
—
—
—
Price/Earnings
22
—
—
—
Price/Book
37
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
6
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare HUTCHMED (China) with its peers
Sawai Pharmaceutical
TYO:4887
44
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Kyowa Hakko Kirin
TYO:4151
50
CountryJapan
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Takeda Pharmaceutical
TYO:4502
48
CountryJapan
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Chong Kun Dang
KSC:185750
55
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Neuren Pharmaceuticals
ASX:NEU
29
CountryAustralia
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Sumitomo Dainippon Pharma
TYO:4506
79
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →